<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>348</serviceExecutionTime><Drug id="8327"><DrugName>KDI-792</DrugName><DrugSynonyms><Name><Value>FK-070</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>KDI-792</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>FR-12170</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>130047-30-2</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="16227">Fujisawa Pharmaceutical Co Ltd</CompanyOriginator><CompaniesSecondary><Company id="16227">Fujisawa Pharmaceutical Co Ltd</Company><Company id="17665">Kissei Pharmaceutical Co Ltd</Company></CompaniesSecondary><CrossReferences><SourceEntity id="8327" type="Drug"><TargetEntity id="188168" type="siDrug">FR-121070</TargetEntity></SourceEntity><SourceEntity id="16227" type="Company"><TargetEntity id="4295876872" type="organizationId">Fujisawa Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="17665" type="Company"><TargetEntity id="4295876120" type="organizationId">Kissei Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="101" type="ciIndication"><TargetEntity id="10012680" type="MEDDRA"></TargetEntity><TargetEntity id="D003929" type="MeSH"></TargetEntity><TargetEntity id="-1144631334" type="omicsDisease"></TargetEntity><TargetEntity id="169" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="260" type="ciIndication"><TargetEntity id="10034636" type="MEDDRA"></TargetEntity><TargetEntity id="D016491" type="MeSH"></TargetEntity><TargetEntity id="-817414410" type="omicsDisease"></TargetEntity><TargetEntity id="260" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="31" type="ciIndication"><TargetEntity id="J45" type="ICD10"></TargetEntity><TargetEntity id="493" type="ICD9"></TargetEntity><TargetEntity id="10003553" type="MEDDRA"></TargetEntity><TargetEntity id="D001249" type="MeSH"></TargetEntity><TargetEntity id="-1473716268" type="omicsDisease"></TargetEntity><TargetEntity id="270" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="325" type="ciIndication"><TargetEntity id="D013923" type="MeSH"></TargetEntity><TargetEntity id="-338631668" type="omicsDisease"></TargetEntity><TargetEntity id="306" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="312" type="Action"><TargetEntity id="3554" type="Mechanism">Platelet Adhesion Inhibitors</TargetEntity><TargetEntity id="3985" type="Mechanism">Drugs Targeting on PolyQ-expanded Proteins</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="101">Diabetic neuropathy</Indication><Indication id="260">Peripheral vascular disease</Indication><Indication id="31">Asthma</Indication><Indication id="325">Thromboembolism</Indication></IndicationsSecondary><ActionsPrimary><Action id="365">Thromboxane A2 antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="312">Platelet aggregation inhibitor</Action><Action id="366">Thromboxane A2 synthesis inhibitor</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>B1C</Code><Name>PLATELET AGGREGATION INHIBITORS</Name></Ephmra></EphmraCodes><LastModificationDate>2017-08-18T05:43:27.000Z</LastModificationDate><ChangeDateLast>2004-09-27T15:40:15.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="8327" linkType="Drug"&gt;KDI-792&lt;/ulink&gt;, a thromboxane A2 (TXA2) receptor antagonist/TXA2 synthetase inhibitor, was being investigated by Kissei, under exclusive rights from Fujisawa, to develop it as a potential antithrombotic [&lt;ulink linkID="165737" linkType="reference"&gt;165737&lt;/ulink&gt;]. By September 1997, Kissei had commenced phase II  trials for arteriosclerosis obliterans and thromboangitis obliterans [&lt;ulink linkID="262810" linkType="reference"&gt;262810&lt;/ulink&gt;]; however, no development has been reported since 2001 [&lt;ulink linkID="422782" linkType="Reference"&gt;422782&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The licensor, Fujisawa, discontinued its development [&lt;ulink linkID="308687" linkType="reference"&gt;308687&lt;/ulink&gt;], following phase II  trials in Japan for the treatment of peripheral vascular disease [&lt;ulink linkID="188560" linkType="reference"&gt;188560&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;ulink linkID="8327" linkType="Drug"&gt;KDI-792&lt;/ulink&gt; produced an increase in lower limb blood flow, with no significant effect on blood pressure or heart rate, in 36 diabetes patients [&lt;ulink linkID="279819" linkType="reference"&gt;279819&lt;/ulink&gt;]. It improved peripheral circulation and nerve conduction in nine patients with diabetic neuropathy [&lt;ulink linkID="189738" linkType="reference"&gt;189738&lt;/ulink&gt;]. It was also indicated as a potential treatment for asthma. &lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="16227">Fujisawa Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="31">Asthma</Indication><StatusDate>1998-12-01T00:00:00.000Z</StatusDate><Source id="308687" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16227">Fujisawa Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="101">Diabetic neuropathy</Indication><StatusDate>1998-12-01T00:00:00.000Z</StatusDate><Source id="308687" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16227">Fujisawa Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="260">Peripheral vascular disease</Indication><StatusDate>1998-12-01T00:00:00.000Z</StatusDate><Source id="308687" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17665">Kissei Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate>2003-03-11T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="16227">Fujisawa Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="101">Diabetic neuropathy</Indication><Source id="189738" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16227">Fujisawa Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="31">Asthma</Indication></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16227">Fujisawa Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="260">Peripheral vascular disease</Indication><Source id="188560" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17665">Kissei Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="325">Thromboembolism</Indication><StatusDate>1997-09-01T00:00:00.000Z</StatusDate><Source id="262810" type="SERIAL"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-01609"><Name>Prostanoid receptor</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><StructureSmiles><Smiles>c1cc(cnc1)CN2C[C@@H](C[C@H]2/C=C\CCCC(=O)O)NS(=O)(=O)c3ccc(cc3)Cl.Cl</Smiles></StructureSmiles><hasSWOTs>N</hasSWOTs></Drug></drugRecordsOutput>